- Connected Health Research - Connected Health Research Frost & Sullivan Technology Innovations Enabling Precision Robotic Surgery This research service offers a strategic perspective of the customer, product, technology and competitors that are influencing the global market for surgical robotics. The report is split into three major sections, each focusing on industry overview, competitive landscape, and voice of stakeholder analysis. The report also includes sections for technology and product segmentation, examining the level the influence of technologies across various product portfolios. The report features an exclusive section on designing the operating theatre of the future, which highlights some of the use cases of advanced technologies being adopted along with surgical robotic systems currently in use across leading healthcare facilities worldwide. 1. To strategically review the role played by NPD (new product development) and research and development (R&D) initiatives in improving the overall adoption of surgical robotics technologies 2. To analyze the ongoing shifts in healthcare needs which are largely driving R&D developments and technology-enabled business models of established and new participants. 3. Strategic investments, technical partnerships, distributor agreements, and IPOs in surgical robotics industry is increasing. What are the strategic priorities of existing/new participants in developing the global market? 4. In addition to the above, this research service also offers insights covering an independent review of industry strategies that are unbiased. This research service also provides details of key industry contacts who also participated in this research. Fri, 28 Sep 2018 00:00:00 +0100 Conventional Medical Imaging Modalities Facing Disruption Fri, 7 Sep 2018 01:33:25 +0100 Movers & Shakers Interview with Steve Forcash VP, Solutions Management & Analytics at Discovery Health Partners Fri, 7 Sep 2018 01:27:19 +0100 Digital Transformation in the Pharmaceuticals Industry Companies-to-Action, 2018 The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.--BEGIN PROMO--

Research Scope

The key objective of this study is to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify pioneering companies that are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. The company profiles offer insights around key solution offerings, target customer segments, service differentiators, and future growth strategies.

Further, the global study provides an analysis of companies segregated by market segments such as: smart R&D, flexible manufacturing, connected patients, and digital pharmacy. The analysis covers technologies such as Artificial intelligence (AI), Big Data and analytics, crowdsourcing, mobile, Industrial IoT (IIoT), IoT, cloud, blockchain, eCommerce, and so on.

The participants mentioned in the study are iSolve, Zephyr Health, PillPack, Proteus Digital Health, BenevolentAI, Elemental Machines, Exscientia, Science 37, Transparency Life Sciences, and uMotif. It also lists the wider universe of companies that were assessed for this analysis. These companies were chosen based factors such as innovative technology development and application, hitting the right focus areas, proven success and industry recognition, and enhanced client collaborations.

Key Issues Addressed

  • How are companies creating extraordinary value for pharmaceutical stakeholders?
  • Which are some unique companies that are introducing new and innovative solutions in the market?
  • How do these companies intend to transform the healthcare industry paradigms in the future? What is the impact of the external industry environment on this market?
  • What is their action plan and potential for growth? What are the current growth opportunities in digital transformation?
  • What are some key success factors in the pharmaceutical market?
  • Which are the companies with whom partnerships can be forged?


Tue, 4 Sep 2018 00:00:00 +0100
Growth Insights for the Direct-to-Consumer Genetic Testing Market, Forecast to 2022 As healthcare evolves toward personalized solutions, everyday consumers are proactively taking responsibility for their health in ways unimaginable a decade ago. A direct-to-consumer genetic test (DTCGT) exemplifies this trend which can be purchased and used directly by consumers without the requirement of a prescription from a healthcare provider. The tests can be purchased online from distribution channels such as DTCGT company websites, e-commerce channels, and online pharmacies. Challenges faced by the industry include unclear regulations, lack of standard guidelines, low test margins, concerns related to scientific validity and consumer data privacy. However, drivers such as increased consumer awareness, approval of health risk genetic tests in the United States, development of significantly modified tests with robust scientific validation and data monetization collaborations with stakeholders such as pharmaceutical companies have provided a strong impetus to the growth of the DTCGT market. With the synergistic effect of advanced technologies such as Artificial Intelligence, Big Data Analytics, and Blockchain on the traditional genetic testing market, along with the adoption of novel distribution models, the market growth is anticipated to increase dramatically in the next five years.--BEGIN PROMO--

Research Scope

The key objective of the growth insights on the DTCGT market is to highlight current market dynamics such as key market participants, market segments and evolving business opportunities. The study aims to identify both established enterprises and start-ups, which are capable of shaping the future through best practices implementation, visionary leadership, and innovation in product offerings. Further, the study provides an analysis of market sizing by revenue segregated by ancestry genetic tests, health risk genetic tests and lifestyle genetic tests. It covers the key drivers, challenges in the market impeding growth, competitive landscape, market participant strategies and future growth strategies. The study also highlights growth opportunities, key trends, mergers and acquisitions, novel distribution models, geographical lucrativeness, notable partnerships, investor funding, collaboration opportunities and key companies to watch. The study is global with deep dives for North America, Europe, Asia Pacific, Middle East and Africa.

Major participants mentioned in the study are 23andMe, Ancestry, National Geographic Geno 2.0, Helix, Mapmygenome, Atlas Biomed, MyHeritage, 23mofang, EasyDNA and DNALabsUAE.

Key Issues Addressed

  • How attractive is the DTCGT market? Which segments are anticipated to grow in the future and their market? 
  • What are the factors driving the demand for DTCGT? What are the business and distribution models that will affect the market?
  • What will be the focal areas of application of technology? Which emerging regions are more lucrative than others?
  • What are the factors impacting solution providers? What are the market dynamics around the key trends as well as market drivers and restraints?
  • Which are the game-changing companies at work? What are the strategic levers to stay on the growth trajectory?
  • What are the key growth opportunities and investment recommendations in this space?
Mon, 27 Aug 2018 00:00:00 +0100
Artificial Intelligence Market Key Application Areas for Growth in Healthcare IT, Forecast to 2022 The study describes how AI technologies are paired with legacy healthcare IT systems to deal with the complexity & growth of medical data. Frost & Sullivan acknowledges that AI intuitively finds ways to convert these ever-expanding resources into actionable evidence for end users. In this study, Frost & Sullivan has forecast global revenue for primary healthcare IT segments* which leverage AI to augment product functionalities. Additionally, the study also features and assesses various progressive AI vendors, offering visionary capabilities that strive to normalize disparate patient data, apply scientific algorithm to generate healthcare evidences and drive cognitive reasoning to predict population health outcomes. The global market revenue has been classified by these end users' corporate receptivity, behavioral agility, and financial ability to fund and sustain AI-enabled HC interventions that promise better outcomes for all. Democratization of AI is on the horizon, which may disrupt the way healthcare has been perceived and delivered. Today, AI-powered digital health solutions primarily allow healthcare enterprises to predict, automate, and prescribe evidence-based business decisions. However, AI-powered digital health solutions from technology maturity and real-word applicability standpoint are still in their infancy. Hence the technology penetration across all end users is low to moderate. It has been estimated that at present only around 20% of these end users would be actively using AI to drive real change in the way healthcare has been conceived and delivered. However, as leading IT companies such as IBM Watson Health, Google, Amazon, Microsoft, Philips, GE Healthcare and Salesforce have started to offer impeccable cloud services and tools to independent AI software developers, more progressive applications, capable of ensuring tangible ROI to end users would flourish and drive the overall market penetration for these technologies. Big-Tech is taking the lead to catalyse innovation in the healthcare AI market. Google is primarily using AI to source and normalize EHR data to identify disease patterns that were historically untraceable. IBM continues to grow its presence in healthcare, driven by a focus on AI-powered clinical decision support, imaging analytics and population health management through its Watson Health business. Additionally, Amazon is making inroads into various aspects of healthcare AI (and could make a big move voice applications, cloud infrastructure solutions and visionary research works) or several big moves-- in this year. Major EHR companies are committing to reduce physicians IT burden by incorporating AI-enabled and voice based medical assistants into their incumbent EHR workflows. Epic recently announced that it has integrated Nuance s AI-powered virtual assistant platform into its EHR. Functionalities include the ability for clinicians to ask for lab results, medication lists, visit summaries and other information in the Epic Haiku mobile app. Athenahealth is also partnering with progressive start-ups that help physicians automate the process of patient scheduling, clinical documentation and coding. Putting Patient Data into Work is a Critical Perquisite of Success for AI-powered health IT solutions. Big-tech must acknowledge that patient generated data which next-generation IT platforms interpret has multiple utilities for diverse healthcare stakeholders. Fully informed consent from patients coupled with 100% compliance with stringent data usage regulation has to be ensured to remain relevant in the market. Frost and Sullivan s new research report on Artificial Intelligence Market Key Application Areas for Growth in Healthcare IT provides a comprehensive analysis on the global healthcare AI market which is primarily segmented into three service verticals that embrace a range of AI technologies to modernize care, personalize treatment and improve outcomes for key end users. Key Regional Markets, Covered in the Research Study The United States of America The United Kingdom France Germany China Switzerland Japan India Types of AI Products Discussed in the Report SaaS Based App Based Integrated Hardware Research-based Doctor-facing Patient-facing Telehealth Key Service Segments (Vendors are Selected by Sub-Segments), covered in the Research Study* Clinical Applications EMR Clinical Decision Support Systems Clinical Analytics Imaging IT Precision Medicine/Genomics IT Wearable Femtech Mental Health Patient Engagement Population Health Management Telehealth Operational Applications Administrative Management Supply Chain Management Enterprise Content Management Cybersecurity Financial Applications Business Intelligence Revenue Cycle Management Coding and Claims Management Key Disease Categories, covered in the Research Study Cancer Cardiology Diabetes Endometriosis Infectious Diseases Rare Diseases *Adoption of AI for the pharmaceutical market, as it relates to digital health, is also discussed but is not included in the market revenue numbers.--BEGIN PROMO--

Key Issues Addressed

  • What are the regional market trends and industry dynamics in global AI for healthcare IT market? What is the future potential for AI-powered healthcare IT solutions? 
  • What is the current market scenario? How much growth is expected? Which are the major market segments? What will be the impact of external trends on each business segment? 
  • Who are the major participants in the global AI for healthcare IT market? What and how are they innovating in this space? 
  • What are the important business model considerations (penetration, pricing and profitability information) for healthcare stakeholders and providers? Who should pay for healthcare AI products? Is there an untapped opportunity in this market?
Fri, 24 Aug 2018 00:00:00 +0100
Future of Electronic Medical Record and Electronic Health Record in Asia-Pacific, Forecast to 2023 The governments and providers in Asia-Pacific (APAC) are focused on reducing medical expenses while improving population health and well-being. A shortage of medical professionals is seen across multiple specialties in various APAC countries; moreover, clinicians are concentrated in urban areas leading to disproportionate clinician to-patient ratios in many areas. To address these challenges, APAC has been investing in healthcare digitalization to increase efficiency, reduce expenses, and automate/eliminate redundant processes. As a result, the adoption of IT is spurring a new wave of development across both public and private hospitals in APAC. The most notable of the IT upgrades are the Electronic Medical Record (EMR) and Electronic Health Record (EHR) technologies. On one hand, an EMR is a legal, digitized record of all encounters an individual has with a particular healthcare provider, supported by one or more of the following applications: clinical data repository (CDR), clinical decision support system (CDSS), controlled medical vocabulary (CMV) and/or computerized physician order entry (CPOE). On the other hand, an EHR is a legal, digital record of all encounters that an individual has with possibly all the healthcare provider organizations within a community, state, or region. This research identified the growing emphasis on patient experience, increasing emphasis on evidence-based care, increasing demand for Population Health Management (PHM) and competition amongst healthcare providers as the top four industry transformations driving EMR and EHR adoption in this region. According to HIMSS APAC, 42 hospitals in the region have achieved Stage 6, and 8 hospitals have achieved Stage 7. More hospitals are moving in the same direction. However, significant investments in EMR, particularly from the public sector, have received widespread criticism from APAC due to the below-expectation returns that they have generated in the past. A key reason for this is the inadequate integration of diverse systems and lack of attention to system interoperability. Therefore, despite investing in the best of solutions healthcare, providers are unable to reap the benefits because they are not able to streamline workflows and gain efficiencies in organizational processes. System interoperability has emerged as a top priority amongst several governments and efforts are being made in this direction by governments, not-for-profit organizations and the private sector. This research also identified poor user interface, cost management and lack of robust training as the top challenges and unmet needs amongst healthcare providers. The report also suggests potential solutions that the EMR/EHR vendors can consider to address the emerging market needs. New technologies such as telehealth, artificial intelligence, and open API continue to make way into the healthcare systems as they hold potentials to further improve clinical and operational efficiencies. These technologies are either capturing clinically significant patient data or leveraging patient data for analysis; both require seamless integration with the EMR/EHR systems. Market development across APAC has been extremely uneven and countries stand at varying levels of adoption and sophistication of EMR and EHR. While developed nations such as Australia, Singapore, Japan, Hong Kong are exploring solutions that help analyze health data to support predictive population health management, developing markets such as Malaysia, Indonesia and Thailand are still focusing on improving their information capture systems.--BEGIN PROMO--

Research Highlights

This report identified key trends shaping the future EMR /EHR market in this region as well as in individual countries and highlight growth opportunities for EMR/EHR vendors. The private sector in APAC will continue to present greater potential as it has the budget to invest in innovative EMRs. Private hospitals will invest in providing high-quality care enabled by technology to attract patients. Japan and China present the greatest opportunity, followed by Australia. These countries are innovating in this space and have a high number of hospital base. South Korea contributes the highest percentage of regional revenue concentrated with local players and it has stringent regulation on data sharing outside of the hospital.

Key Conclusion

In the next 5 year, EMR vendors in APAC will compete by offering different EMR software packages for developed and developing nations: highly scalable and affordable EMR packages for developing nations and sophisticated EMR packages for developed nations.

Tue, 21 Aug 2018 00:00:00 +0100
Artificial Intelligence for Medical Image Analysis Companies-to-Action, 2018 Medical imaging has become the bellwether application for artificial intelligence (AI) technologies in healthcare. From deep learning and machine learning approaches, to cognitive computing, to even natural language processing, several AI approaches are now being incorporated in the field of radiology. Apart from academic research groups, almost all major manufacturers and vendors in the medical imaging space have or are developing initiatives to bring automation, augmentation or acceleration to medical imaging, cognitive computing for imaging informatics applications and even intelligent machines. There are several startups as well which continue to advance the development of solutions. In the medical imaging workflow, from ordering of imaging studies all the way up to follow-up post imaging, artificial intelligence could play a role. Of course, current efforts are mostly concentrated in analyzing the medical images. These solutions have been deployed on premises, but there is a gradual adoption of cloud technologies too. As applications evolve and are developed further, AI is moving to the edge, and might also become embedded in imaging equipment as the next frontier. However, at the global level, countries look up to AI to address very different and systemic challenges while some such as the United States require higher productivity and standardization, the United Kingdom needs to address shortages and higher wait time, whereas others such as China need it to build access and expertize to improve diagnosis rates. This has naturally resulted in a continuous growth in the number of startups emerging in this field, globally. Funding too, has flowed in to support the momentum. Crucial regulatory milestones have been achieved, but many more are likely to be reached as well. This study is a focused analysis to highlight all of the companies active in this space, and to analyze their solutions to get a sense of the trends in the industry. Aptly called the Companies-to-Action, a comprehensive analysis of ~100 AI companies currently offering medical image analysis solutions provides an in-depth insight in to several key questions, as outlined below. Competitive landscape, evolving partnerships, regional analysis to identify conducive factors for development of AI solutions, funding trends for the 80+ startups, a landscape assessment, and finally, a list of top ten predictions for the coming 5 years are covered in this study. It also highlights a curated list of companies along with our perspective on their uniqueness, potential opportunities, and threats.--BEGIN PROMO--

Key Issues Addressed

  • Who are the companies that have set out to develop and commercialize artificial intelligence-based solutions for medical image analysis?
  • Which modalities, organs and disease areas have vendors focused on during the inception phase 2011-2018?
  • What kind of competitive and partnership dynamics are taking place across the vendor, provider and investor ecosystems?
  • What are some unique approaches and use cases addressed by some of the most innovative companies vested in AI-based medical image analysis?
  • How do various regions fare in the adoption of, and investment in AI based technologies for medical image analysis?
Tue, 21 Aug 2018 00:00:00 +0100